WaveClear Vascular is developing a proprietary ultrasonic catheter platform for removing vascular blood clots and calcified occlusions. Its approach combines more than one million controlled micro-cavitations per minute with acoustic micro-streaming and catheter motion, aiming to clear vessels while preserving vessel integrity and allowing targeted drug infusion. Founded by chief biophysicist Jeffrey Vaitekunas, whose career includes more than 25 patents and work on Johnson & Johnson’s UltraCision device, the company is led by a team with deep medical-device and vascular-care experience.
NeuRx MedicalNeuRx Medical is developing the NeuRx Sweeper™, a low-profile adjunct catheter designed to remove organized, adherent clot during thrombectomy for deep-vein thrombosis and pulmonary embolism. Founded by medical-device commercialization executive Timothy Clark, the company uses a radially expanding nitinol capture node to apply mechanical traction where aspiration alone can leave residual thrombus. The investigational device has completed bench and animal feasibility testing, while NeuRx advances it toward FDA 510(k) clearance.
Cagent VascularCagent Vascular develops endovascular medical devices for peripheral artery disease, centered on its Serranator balloon catheters and Serration Remodeling Therapy. Co-founded by vascular surgeon Peter Schneider and inventor Robert Giasolli, the Wayne, Pennsylvania company uses focused point force rather than conventional circumferential stretching to open arteries at low pressure. Its platform includes a purpose-built catheter for difficult pedal and critical limb-threatening ischemia cases, alongside technologies still in development.WAYNE, PA
ThrombolexBuilt around physician Riyaz Bashir’s BASHIR™ platform, Thrombolex makes endovascular catheters that combine mechanical clot fragmentation with targeted thrombolytic delivery for arterial and venous thromboembolic conditions. The New Britain, Pennsylvania medical-device manufacturer markets multiple FDA-cleared devices, including catheters with expandable infusion baskets designed to restore blood flow in peripheral and pulmonary vessels. Its leadership and clinical programs draw on more than 100 years of combined experience and partnerships across the medical field.NEW BRITAIN, PA
VasocureVasocure is a novel therapeutics company developing peptide medicines for vascular disease, centered on Pedifin, its patented F11R blocker for neointimal disease and atherosclerosis. Founded by nephrologists and scientists involved in discovering the human F11 receptor, the company draws on more than two decades of research into vascular access failure in dialysis patients. Its 62-candidate pipeline spans nephrology, cardiology, and oncology, with Pedifin in preclinical and first-in-human studies.NEW YORK, NY